Identification of three classes of heteroaromatic compounds with activity against intracellular Trypanosoma cruzi by chemical library screening

PLoS Neglected Tropical Diseases

Volumn 3, Issue 2, 2009, Pages

  Bettiol, Esther ^a   Samanovic, Marie ^a   Murkin, Andrew S ^b   Raper, Jayne ^a   Buckner, Frederick ^c   Rodriguez, Ana ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [6 (4 CHLORO 3,5 DIMETHYLPHENOXY)HEXYL] 1H IMIDAZOLE; 2 (3 NITRO 1H 1,2,4 TRIAZOL 1 YL) N [3 NITRO 5 [3 (TRIFLUOROMETHYL)PHENOXY]PHENYL]ACETAMIDE; BETA GALACTOSIDASE; N [[5 (2,3 DICHLOROPHENYL) 2 FURANYL]METHYLENE] 2 PYRIDINECARBOHYDRAZIDE; UNCLASSIFIED DRUG; ANTITRYPANOSOMAL AGENT; AROMATIC HYDROCARBON; HETEROCYCLIC COMPOUND;

ANIMAL CELL; ARTICLE; CHAGAS DISEASE; CONTROLLED STUDY; CYTOTOXICITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; FLAGELLATE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; STRUCTURE ANALYSIS; TRYPANOSOMA CRUZI; TRYPOMASTIGOTE; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CELL LINE; CELL STRAIN 3T3; CHEMISTRY; DRUG EFFECT; DRUG SENSITIVITY; FLUORESCENT ANTIBODY TECHNIQUE; GROWTH, DEVELOPMENT AND AGING; HAPLORHINI; LEISHMANIA MAJOR; MACROPHAGE; PARASITOLOGY;

ANIMALS; CELL LINE; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; FLUORESCENT ANTIBODY TECHNIQUE; HAPLORHINI; HETEROCYCLIC COMPOUNDS; HYDROCARBONS, AROMATIC; LEISHMANIA MAJOR; MACROPHAGES; MICE; MICE, INBRED BALB C; NIH 3T3 CELLS; PARASITIC SENSITIVITY TESTS; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 65549111678     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000384     Document Type: Article

References (29)

1. TDR WHO's Special Program for Research and Training in Tropical Diseases (2005) Report of the Scientific Working Group on Chagas Disease.
2. Tarleton RL, Reithinger R, Urbina JA, Kitron U, Gurtler RE (2007) The challenges of Chagas Disease - grim outlook or glimmer of hope. PLoS Med 4: e332. doi:10.1371/journal.pmed.0040332.
3. De Souza W (2002) Basic cell biology of Trypanosoma cruzi. Curr Pharm Des 8: 269-285.
4. Minodier P, Parola P (2007) Cutaneous leishmaniasis treatment. Travel Med Infect Dis 5: 150-158.
5. Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, et al. (2007) Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 5: 873-882.
6. Sundar S, Rai M, Chakravarty J, Agarwal D, Agrawal N, et al. (2008) New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis 47: 1000-1006.
7. Buckner FS, Verlinde CL, La Flamme AC, Van Voorhis WC (1996) Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase. Antimicrob Agents Chemother 40: 2592-2597.
8. McFadden DC, Seeber F, Boothroyd JC (1997) Use of Toxoplasma gondii expressing beta-galactosidase for colorimetric assessment of drug activity in vitro. Antimicrob Agents Chemother 41: 1849-1853.
9. Seeber F, Boothroyd JC (1996) Escherichia coli beta-galactosidase as an in vitro and in vivo reporter enzyme and stable transfection marker in the intracellular protozoan parasite Toxoplasma gondii. Gene 169: 39-45.
10. Buckner FS, Wilson AJ, Van Voorhis WC (1999) Detection of live Trypanosoma cruzi in tissues of infected mice by using histochemical stain for beta-galactosidase. Infect Immun 67: 403-409.
11. Vega C, Rolon M, Martinez-Fernandez AR, Escario JA, Gomez-Barrio A (2005) A new pharmacological screening assay with Trypanosoma cruzi epimastigotes expressing beta-galactosidase. Parasitol Res 95: 296-298.
12. Kapler GM, Coburn CM, Beverley SM (1990) Stable transfection of the human parasite Leishmania major delineates a 30-kilobase region sufficient for extrachromosomal replication and expression. Mol Cell Biol 10: 1084-1094.
13. Spath GF, Beverley SM (2001) A lipophosphoglycan-independent method for isolation of infective Leishmania metacyclic promastigotes by density gradient centrifugation. Exp Parasitol 99: 97-103.
14. Huynh C, Sacks DL, Andrews NW (2006) A Leishmania amazonensis ZIP family iron transporter is essential for parasite replication within macrophage phagolysosomes. J Exp Med 203: 2363-2375.
15. Zhang JH, Chung TD, Oldenburg KR (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67-73.
16. Da Silva RP, Hall BF, Joiner KA, Sacks DL (1989) CR1, the C3b receptor, mediates binding of infective Leishmania major metacyclic promastigotes to human macrophages. J Immunol 143: 617-622.
17. Mosser DM, Edelson PJ (1987) The third component of complement (C3) is responsible for the intracellular survival of Leishmania major. Nature 327: 329-331.
18. Mersch-Sundermann V, Knasmuller S, Wu XJ, Darroudi F, Kassie F (2004) Use of a human-derived liver cell line for the detection of cytoprotective, antigenotoxic and cogenotoxic agents. Toxicology 198: 329-340.
19. Buckner FS, Wilson AJ (2005) Colorimetric assay for screening compounds against Leishmania amastigotes grown in macrophages. Am J Trop Med Hyg 72: 600-605.
20. Nair RR, Avila H, Ma X, Wang Z, Lennartz M, et al. (2008) A novel high-throughput screening system identifies a small molecule repressive for matrix metalloproteinase-9 expression. Mol Pharmacol 73: 919-929.
21. Kao RY, Jenkins JL, Olson KA, Key ME, Fett JW, et al. (2002) A small-molecule inhibitor of the ribonucleolytic activity of human angiogenin that possesses antitumor activity. Proc Natl Acad Sci U S A 99: 10066-10071.
22. Castell JV, Jover R, Martinez-Jimenez CP, Gomez-Lechon MJ (2006) Hepatocyte cell lines: their use, scope and limitations in drug metabolism studies. Expert Opin Drug Metab Toxicol 2: 183-212.
23. Goad LJ, Berens RL, Marr JJ, Beach DH, Holz GG Jr (1989) The activity of ketoconazole and other azoles against Trypanosoma cruzi: biochemistry and chemotherapeutic action in vitro. Mol Biochem Parasitol 32: 179-189.
24. Campos R, Amato Neto V, Moreira AA, de Souza HB, Okumura M, et al. (1992) [Evaluation of the therapeutic activity of fluconazole in acute experimental infection caused by Trypanosoma cruzi]. Rev Hosp Clin Fac Med Sao Paulo 47: 174-175.
25. Castro JA, de Mecca MM, Bartel LC (2006) Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis). Hum Exp Toxicol 25: 471-479.
26. Finlayson K, Witchel HJ, McCulloch J, Sharkey J (2004) Acquired QT interval prolongation and HERG: implications for drug discovery and development. Eur J Pharmacol 500: 129-142.
27. Grellier P, Sinou V, Garreau-de Loubresse N, Bylen E, Boulard Y, et al. (1999) Selective and reversible effects of vinca alkaloids on Trypanosoma cruzi epimastigote forms: blockage of cytokinesis without inhibition of the organelle duplication. Cell Motil Cytoskeleton 42: 36-47.
28. Baum SG, Wittner M, Nadler JP, Horwitz SB, Dennis JE, et al. (1981) Taxol, a microtubule stabilizing agent, blocks the replication of Trypanosoma cruzi. Proc Natl Acad Sci U S A 78: 4571-4575.
29. Blair IA, Mansilla Tinoco R, Brodie MJ, Clare RA, Dollery CT, et al. (1985) Plasma hydrazine concentrations in man after isoniazid and hydralazine administration. Hum Toxicol 4: 195-202.